Currently out of the existing stock ratings of Matthew Caufield, 65 are a BUY (91.55%), 6 are a HOLD (8.45%).

Matthew Caufield

Work Performance Price Targets & Ratings Chart

Analyst Matthew Caufield, carries an average stock price target met ratio of 25.6% that have a potential upside of 15.89% achieved within 38 days. Previously, Matthew Caufield worked at HC WAINWRIGHT.

Matthew Caufield’s has documented 137 price targets and ratings displayed on 14 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on OPT, Opthea Ltd at 28-Feb-2025.

Wall Street Analyst Matthew Caufield

Analyst best performing recommendations are on EYEN (EYENOVIA).
The best stock recommendation documented was for EYEN (EYENOVIA) at 11/13/2024. The price target of $12 was fulfilled within 2 days with a profit of $20.6 (63.19%) receiving and performance score of 315.95.

Average potential price target upside

ALDX Aldeyra The EYEN Eyenovia FDMT 4D Molecular Therapeutics  ISEE IVERIC bio OCUP Ocuphire Pharma OPT Opthea Ltd LYRA Lyra Therapeutics  UBX Unity Biotechnology GMTX Gemini Therapeutics ADVM Adverum Biotechnologies DMAC DiaMedica Therapeutics KOD Kodiak Sciences OPTN OptiNose PHAT Phathom Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$10

$4.89 (95.69%)

$10

6 months 22 days ago
(09-Aug-2024)

0/9 (0%)

$4.9 (96.08%)

Buy

$10

$4.89 (95.69%)

6 months 23 days ago
(08-Aug-2024)

0/1 (0%)

$5.81 (138.66%)

Buy

$8

$2.89 (56.56%)

$25

1 years 4 months 14 days ago
(17-Oct-2023)

0/10 (0%)

$6.16 (334.78%)

Hold

$14

1 years 4 months 14 days ago
(17-Oct-2023)

2/3 (66.67%)

$6.42 (84.70%)

362

Buy

3 years 2 months 5 days ago
(27-Dec-2021)

0/1 (0%)

$9.48 (75.72%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Matthew Caufield is most bullish on?

Potential upside of $25.29 has been obtained for ADVM (ADVERUM BIOTECHNOLOGIES)

Which stock is Matthew Caufield is most reserved on?

Potential downside of -$1.11 has been obtained for KOD (KODIAK SCIENCES)

What Year was the first public recommendation made by Matthew Caufield?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?